for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc (ADR)

GSK

Latest Trade

38.39USD

Change

-0.95(-2.41%)

Volume

4,363,194

Today's Range

38.37

 - 

38.70

52 Week Range

33.26

 - 

42.68

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Bluebell Capital Says Believes GSK Should Address Leadership For “New GSK” - Letter

Sept 22 (Reuters) - BLUEBELL CAPITAL::BLUEBELL CAPITAL SENDS LETTER TO CHAIRMAN OF GSK.BLUEBELL CAPITAL SAYS BELIEVES GSK SHOULD ADDRESS IN THE SHORT TERM, THE LEADERSHIP FOR “NEW GSK”.BLUEBELL CAPITAL: ASK GSK BOARD TO ACCELERATE FURTHER APPOINTMENTS TO GSK BOARD WITH OBJECTIVE TO INCREASE BIOPHARMACEUTICALS, SCIENTIFIC EXPERIENCE.BLUEBELL CAPITAL: ASKS GSK TO LAUNCH IMMEDIATELY AFTERWARDS THOROUGH, ROBUST PROCESS TO IDENTIFY BEST(INTERNAL OR EXTERNAL) CANDIDATE TO LEAD NEW GSK.BLUEBELL CAPITAL: ASKS GSK TO TAKE A PROACTIVE APPROACH TO CONSIDER AVAILABLE ALTERNATIVE TRANSACTIONS TO DEMERGER OF CONSUMER HEALTHCARE.BLUEBELL CAPITAL SAYS VIEWS GSK VACCINE FRANCHISE AS GENERALLY UNDERVALUED BY MARKET - LETTER.BLUEBELL WRITES TO GSK IN RELATION TO INVESTMENT AND/OR ECONOMIC INTEREST IN GSK COMMON EQUITY SHARES BY BLUEBELL ACTIVE EQUITY MASTER FUND ICAV.BLUEBELL CAPITAL SAYS BELIEVES GSK'S EMMA WALMSLEY WOULD HAVE BEEN A VERY CREDIBLE CANDIDATE FOR THE POSITION OF CEO AT CONSUMER HEALTHCARE.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

GSK Announces £50m Investment In Renewable Energy And Carbon Reduction

Sept 20 (Reuters) - GlaxoSmithKline PLC <GSK.L>::PRESS RELEASE: GSK ANNOUNCES MAJOR RENEWABLE ENERGY INVESTMENT AND LOW CARBON INHALER PROGRAMME ALONGSIDE LIFE SCIENCES SECTOR RACE TO ZERO ‘BREAKTHROUGH’ AT NYC CLIMATE WEEK.GSK - ANNOUNCES £50M INVESTMENT IN RENEWABLE ENERGY AND CARBON REDUCTION.GSK - ALSO ANNOUNCED TO REDUCE GREENHOUSE GAS EMISSIONS FROM RESCUE METERED DOSE INHALERS, RESPONSIBLE FOR 45% OF GSK'S CARBON EMISSIONS.GSK - NEW PROGRAMMES SUPPORT DELIVERY OF GSK GOALS OF ACHIEVING NET ZERO IMPACT ON CLIMATE AND NET POSITIVE IMPACT ON NATURE BY 2030.

SK Bio, GSK Start Late-Stage COVID-19 Vaccine Trial

Aug 31 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL.GSK - ADVANCE TO PHASE 3 FOLLOWS POSITIVE INTERIM PHASE 1/2 IMMUNOGENICITY AND SAFETY DATA.GLAXOSMITHKLINE PLC - SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL.GSK - GLOBAL CLINICAL TRIAL WILL EVALUATE VACCINE CANDIDATE GBP510 AGAINST AZ/OXFORD COVID-19 VACCINE.GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN FIRST HALF OF 2022, SUBJECT TO DATA AND REGULATORY REVIEW.GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN FIRST HALF OF 2022.GSK - NO SAFETY CONCERNS HAVE BEEN IDENTIFIED TO DATE IN THIS ONGOING STUDY..GSK - ALSO ASSESSING WHETHER AN INVESTIGATIONAL MONOCLONAL ANTIBODY, OTILIMAB, CAN HELP SEVERELY ILL COVID-19 PATIENTS AGED OVER 70.GSK - GSK IS ALSO EXPLORING POTENTIAL THERAPEUTIC OR TREATMENT OPTIONS FOR COVID-19 PATIENTS.

Australia's Health Department Says It Has Approved Glaxosmithkline's COVID-19 Treatment, Sotrovimab (Xevudy)

Aug 19 (Reuters) - :AUSTRALIA'S HEALTH DEPARTMENT SAYS IT HAS APPROVED GLAXOSMITHKLINE'S COVID-19 TREATMENT, SOTROVIMAB (XEVUDY).Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

iTeos Therapeutics's Unit Got Upfront Payment Of $625 Mln From Glaxosmithkline Intellectual Property Limited

Aug 10 (Reuters) - GlaxoSmithKline PLC <GSK.L>::ITEOS THERAPEUTICS - ON AUG 6, ITEOS BELGIUM, CO'S UNIT GOT UPFRONT PAYMENT OF $625 MILLION FROM GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED.ITEOS THERAPEUTICS - CO'S UNIT RECEIVED UPFRONT PAYMENT PURSUANT TO COLLABORATION AND LICENSE AGREEMENT WITH GLAXOSMITHKLINE INTELLECTUAL PROPERTY.ITEOS THERAPEUTICS - FOLLOWING RECEIPT OF UPFRONT PAYMENT, CO BELIEVES EXISTING CASH, CASH EQUIVALENTS ENABLE TO FUND OPERATING, CAPITAL EXPENDITURE REQUIREMENTS INTO 2026.

Gsk - Files For Licensure Of Mmr Vaccine In U.S.

Aug 2 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK - FILES FOR LICENSURE OF MMR VACCINE IN U.S..GSK - SUBMITTED A BLA TO U.S. FDA FOR PRIORIX, SEEKING APPROVAL FOR USE IN ACTIVE IMMUNIZATION AGAINST INFECTION BY MEASLES, MUMPS AND RUBELLA (MMR).

GSK Reports FDA approval for Nucala for use in adults with chronic rhinosinusitis with nasal polyps

July 29 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK ANNOUNCES FDA APPROVAL FOR NUCALA (MEPOLIZUMAB) FOR USE IN ADULTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS.

GSK Sees 2021 Adj EPS To Decline By Mid-To-High Single-Digit Percentage

July 28 (Reuters) - GlaxoSmithKline PLC <GSK.L>::2ND QUARTER RESULTS.Q2 EARNINGS PER SHARE FELL 39 PERCENT TO 27.9 PENCE.GSK SAYS CONTINUES TO EXPECT DIVIDEND OF 80P/SHARE FOR 2021 .Q2 SALES ROSE 6 PERCENT TO 8.1 BILLION STG.Q2 ADJUSTED EARNINGS PER SHARE ROSE 46 PERCENT TO 28.1 PENCE.GSK - DIVIDEND OF 19P/SHARE DECLARED FOR Q2 2021.GSK - DIVIDEND OF 19P/SHARE DECLARED FOR Q2 2021. CONTINUE TO EXPECT 80P/SHARE FOR 2021.GSK - QTRLY SALES FROM PHARMACEUTICALS £4.2 BILLION +3% AER, +12% CER.GSK - CONFIDENT IN DELIVERING 2021 EPS GUIDANCE AND RECONFIRM 2022 OUTLOOK.GSK - QTRLY SALES FROM VACCINES £1.6 BILLION +39% AER, +49% CER.GSK - 2021 GUIDANCE AND 2022 OUTLOOK EXCLUDE ANY CONTRIBUTION FROM COVID-19 SOLUTIONS.GSK - 2021 ADJUSTED EPS TO DECLINE BY MID-TO-HIGH SINGLE-DIGIT PERCENTAGE AT CER.GSK - QTRLY SALES FROM CONSUMER HEALTHCARE £2.3 BILLION -4% AER, +3% CER.GSK - 2022 MEANINGFUL IMPROVEMENTS EXPECTED IN REVENUES AND MARGINS.GSK - CONTINUE TO STRENGTHEN OUR PIPELINE AND ARE ADVANCING WELL TOWARDS SEPARATION.GSK - CONTINUE TO EXPECT STRONG GROWTH FROM SHINGRIX IN H2.GSK - IN H1 2021, WE HAD COVID-19 SOLUTION SALES OF £276 MILLION.GSK - EXPECT POSITIVE MOMENTUM TO CONTINUE THROUGH SECOND HALF OF YEAR DRIVING US TOWARDS BETTER END OF EARNINGS GUIDANCE RANGE FOR 2021.GSK - FOR FULL YEAR, WE EXPECT THAT COVID-19 SOLUTIONS WILL CONTRIBUTE APPROXIMATELY BETWEEN 4% TO 6% OF ADJUSTED EPS GROWTH.GSK - COVID-19 SOLUTION CONTRIBUTION TO H1 ADJUSTED EPS WAS APPROXIMATELY 7%.

GSK Sees 2021 Adj EPS To Decline By Mid-To-High Single-Digit Percentage

July 28 (Reuters) - GlaxoSmithKline PLC <GSK.L>::2ND QUARTER RESULTS.Q2 SALES ROSE 6 PERCENT TO 8.1 BILLION STG.Q2 EARNINGS PER SHARE FELL 28 PERCENT TO 27.9 PENCE.Q2 ADJUSTED EARNINGS PER SHARE ROSE 46 PERCENT TO 28.1 PENCE.GSK - CONTINUE TO EXPECT 80P/SHARE FOR 2021.GSK - DIVIDEND OF 19P/SHARE DECLARED FOR Q2 2021..GSK - DIVIDEND OF 19P/SHARE DECLARED FOR Q2 2021. CONTINUE TO EXPECT 80P/SHARE FOR 2021.GSK - QTRLY SALES FROM PHARMACEUTICALS £4.2 BILLION +3% AER, +12% CER.GSK - CONFIDENT IN DELIVERING 2021 EPS GUIDANCE AND RECONFIRM 2022 OUTLOOK.GSK - QTRLY SALES FROM VACCINES £1.6 BILLION +39% AER, +49% CER.GSK - 2021 GUIDANCE AND 2022 OUTLOOK EXCLUDE ANY CONTRIBUTION FROM COVID-19 SOLUTIONS.GSK - 2021 ADJUSTED EPS TO DECLINE BY MID-TO-HIGH SINGLE-DIGIT PERCENTAGE AT CER.GSK - QTRLY SALES FROM CONSUMER HEALTHCARE £2.3 BILLION -4% AER, +3% CER.GSK - 2022 MEANINGFUL IMPROVEMENTS EXPECTED IN REVENUES AND MARGINS.GSK - CONTINUE TO STRENGTHEN OUR PIPELINE AND ARE ADVANCING WELL TOWARDS SEPARATION.GSK - CONTINUE TO EXPECT STRONG GROWTH FROM SHINGRIX IN H2.GSK - IN H1 2021, WE HAD COVID-19 SOLUTION SALES OF £276 MILLION.GSK - EXPECT POSITIVE MOMENTUM TO CONTINUE THROUGH SECOND HALF OF YEAR DRIVING US TOWARDS BETTER END OF EARNINGS GUIDANCE RANGE FOR 2021.GSK - FOR FULL YEAR, WE EXPECT THAT COVID-19 SOLUTIONS WILL CONTRIBUTE APPROXIMATELY BETWEEN 4% TO 6% OF ADJUSTED EPS GROWTH.GSK - COVID-19 SOLUTION CONTRIBUTION TO H1 ADJUSTED EPS WAS APPROXIMATELY 7%.

GSK And Vir Biotechnology Announce Joint Procurement Deal With European Commission For Sotrovimab

July 28 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK AND VIR BIOTECHNOLOGY ANNOUNCE JOINT PROCUREMENT AGREEMENT WITH EUROPEAN COMMISSION FOR COVID-19 TREATMENT, SOTROVIMAB.GSK - AGREEMENT WITH THE EUROPEAN COMMISSION TO SUPPLY UP TO 220,000 DOSES OF SOTROVIMAB.GSK - CONTINUING TO EVALUATE ABILITY OF SOTROVIMAB TO MAINTAIN ACTIVITY AGAINST NEW AND EMERGING VARIANTS THROUGH IN VITRO STUDIES.GSK - CONTINUING TO EVALUATE ABILITY OF SOTROVIMAB TO MAINTAIN ACTIVITY AGAINST NEW AND EMERGING VARIANTS THROUGH IN VITRO STUDIES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up